These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22842629)

  • 1. Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management.
    Adhami VM; Syed DN; Khan N; Mukhtar H
    Biochem Pharmacol; 2012 Nov; 84(10):1277-81. PubMed ID: 22842629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.
    Khan N; Afaq F; Khusro FH; Mustafa Adhami V; Suh Y; Mukhtar H
    Int J Cancer; 2012 Apr; 130(7):1695-705. PubMed ID: 21618507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin.
    Syed DN; Adhami VM; Khan MI; Mukhtar H
    Anticancer Agents Med Chem; 2013 Sep; 13(7):995-1001. PubMed ID: 23293889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The flavonoid fisetin as an anticancer agent targeting the growth signaling pathways.
    Rengarajan T; Yaacob NS
    Eur J Pharmacol; 2016 Oct; 789():8-16. PubMed ID: 27377217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-κB/mTOR and ERK1/2 signaling pathways.
    Zhang XJ; Jia SS
    Biomed Pharmacother; 2016 Oct; 83():1164-1174. PubMed ID: 27551764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells.
    Suh Y; Afaq F; Khan N; Johnson JJ; Khusro FH; Mukhtar H
    Carcinogenesis; 2010 Aug; 31(8):1424-33. PubMed ID: 20530556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fisetin, a 3,7,3',4'-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models.
    Chamcheu JC; Esnault S; Adhami VM; Noll AL; Banang-Mbeumi S; Roy T; Singh SS; Huang S; Kousoulas KG; Mukhtar H
    Cells; 2019 Sep; 8(9):. PubMed ID: 31540162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fisetin regulates obesity by targeting mTORC1 signaling.
    Jung CH; Kim H; Ahn J; Jeon TI; Lee DH; Ha TY
    J Nutr Biochem; 2013 Aug; 24(8):1547-54. PubMed ID: 23517912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells.
    Chien CS; Shen KH; Huang JS; Ko SC; Shih YW
    Mol Cell Biochem; 2010 Jan; 333(1-2):169-80. PubMed ID: 19633975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
    Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.
    Wu R; Hu TC; Rehemtulla A; Fearon ER; Cho KR
    Clin Cancer Res; 2011 Dec; 17(23):7359-72. PubMed ID: 21903772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition.
    Tang KD; Ling MT
    Curr Med Chem; 2014; 21(26):3048-56. PubMed ID: 24735368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the molecular targets of dietary flavonoid fisetin in cancer.
    Syed DN; Adhami VM; Khan N; Khan MI; Mukhtar H
    Semin Cancer Biol; 2016 Oct; 40-41():130-140. PubMed ID: 27163728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention.
    Tong X; Pelling JC
    Anticancer Agents Med Chem; 2013 Sep; 13(7):971-8. PubMed ID: 23272913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway.
    Cai F; Zhang Y; Li J; Huang S; Gao R
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32039440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fisetin inhibits human melanoma cell growth through direct binding to p70S6K and mTOR: findings from 3-D melanoma skin equivalents and computational modeling.
    Syed DN; Chamcheu JC; Khan MI; Sechi M; Lall RK; Adhami VM; Mukhtar H
    Biochem Pharmacol; 2014 Jun; 89(3):349-60. PubMed ID: 24675012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
    Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in Anticancer Drug-Induced Toxicity by Fisetin in Lung Adenocarcinoma A549 Spheroid Cells Mediated by the Reduction of Claudin-2 Expression.
    Eguchi H; Kimura R; Matsunaga H; Matsunaga T; Yoshino Y; Endo S; Ikari A
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fisetin and Its Role in Chronic Diseases.
    Pal HC; Pearlman RL; Afaq F
    Adv Exp Med Biol; 2016; 928():213-244. PubMed ID: 27671819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.